3 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
Follow Urothelial Carcinoma Bladder: new trials by email Literature Review of Urothelial Carcinoma Bladder trials Research Report on Urothelial Carcinoma Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) UGN-301, UGN-201, Gemcitabine - Non-muscle Invasive Bladder Cancer, NMIBC | Phase 1 | Completed | UroGen Pharma Ltd. | 51 | 2022-06-01 | 2026-01-14 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma IK-175, IK-175 and nivolumab - Urothelial Carcinoma, Urothelial Carcinoma Bladder | Phase 1 | Completed | Ikena Oncology | 78 | 2019-12-18 | 2024-03-15 |
| Phase Ib of L-NMMA and Pembrolizumab L-NMMA, Pembrolizumab - Non-Small Cell Lung Cancer, Malignant Melanoma | Phase 1 | Completed | The Methodist Hospital Research Institute | 12 | 2018-08-27 | 2026-04-09 |
Urinary Bladder Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · DNA Repair-Deficiency Disorders (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Urinary Bladder Diseases (1)
Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Male Urogenital Diseases (2) · Neoplasms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Urologic Diseases (2) · Urologic Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1)
Gemcitabine (1) · Imiquimod (1) · Nivolumab (1) · omega-N-Methylarginine (1) · pembrolizumab (1)
Ikena Oncology (1) · The Methodist Hospital Research Institute (1) · UroGen Pharma Ltd. (1)
United States (3) · Italy (1) · Spain (1)
Jun Zhang, M.D. (1) · Karim Malek, MD (1) · Sebastian Mirkin, MD (1)